Evidence map›Paper›PMID 42324681›Full record

Observational studyFuture oncology (London, England)2026

Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.

Julia Foldi, Gregory Hogan, Katherine Johansen Taber, Matthew LaBella, Britney Sadler, Ravi Patel, Marija Balic, Derrick Haslem, Marcela Mazo Canola, Judy Peih-Ying Tsai and 11 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Julia FoldiDepartment of Medicine, Division of Malignant Hematology and Medical Oncology, University of Pittsburgh Medical Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.ORCID 0000-0002-7504-867X
Gregory HoganResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
Katherine Johansen TaberResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.ORCID 0000-0003-3051-2667
Matthew LaBellaResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
Britney SadlerResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
Ravi PatelResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
Marija BalicDepartment of Medicine, Division of Malignant Hematology and Medical Oncology, University of Pittsburgh Medical Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Derrick HaslemOncology Service Line, Intermountain Healthcare, Saint George, UT, USA.
Marcela Mazo CanolaDivision of Hematology and Oncology, Mays Cancer Center, University of Texas at San Antonio, San Antonio, TX, USA.
Judy Peih-Ying TsaiDepartment of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
Therese CusickDepartment of Surgery, Ascension Via Christi Hospitals Wichita, Inc.., Wichita, KS, USA.
Niyati NathwaniCarolina Blood and Cancer Care Associates, Lancaster, SC, USA.
Yoichi NaitoDepartment of Medical Oncology, Department of General Internal Medicine, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
Chikako FunasakaDepartment of Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
Karlton WongDepartment of Medical Oncology, Providence Saint Joseph's Medical Center, Burbank, CA, USA.
Alexander HamResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
Ashley AcevedoResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
C J BatteyResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
Genevieve M GouldResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.
Dale MuzzeyResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.ORCID 0000-0001-8822-2035
Jeff JasperResearch and Development, Myriad Genetics, Salt Lake City, UT, USA.ORCID 0000-0003-3941-0018

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePathological complete response (pCR) after neoadjuvant therapy (NAT) strongly associates with reduced breast cancer relapse risk. Circulating tumor DNA (ctDNA) shows promise as a therapy-response biomarker, but prior studies had limited sampling and assay sensitivity. MONITOR-Breast characterized ctDNA dynamics across NAT at high temporal resolution using an ultrasensitive molecular residual disease (MRD) assay. EXPERIMENTAL

designIn this prospective observational study, 154 enrolled patients with breast cancer (all subtypes, Stages I-III) were tested at baseline, throughout NAT, and post-surgery using a whole genome sequencing-based MRD assay tracking up to 1,000 variants per patient.

resultsBaseline ctDNA was detected in 93% of patients, with 20% detected in the ultrasensitive range (<100 parts per million). Post-NAT ctDNA positivity strongly associated with residual disease (RD) (odds ratio (OR)>20,

conclusionsFrequent, ultrasensitive ctDNA assessment provided comprehensive characterization of treatment response, revealing opportunities for de-escalation in early responders and escalation in those with persistent ctDNA.

Indexed as

Biomarkers, TumorBreast NeoplasmsCirculating Tumor DNAAdultAgedFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm, ResidualNeoplasm StagingPathologic Complete ResponsePrecision MedicineProspective StudiesWhole Genome SequencingBiomarkers, TumorCirculating Tumor DNAbreast cancerctDNAmolecular residual diseaseneoadjuvant therapyresponse monitoring

Identifiers

PMID42324681
PMCPMC13390526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.